Prestige Wealth Management Group LLC Raises Stock Holdings in Danaher Co. (NYSE:DHR)

Prestige Wealth Management Group LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 22.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,528 shares of the conglomerate’s stock after purchasing an additional 276 shares during the quarter. Prestige Wealth Management Group LLC’s holdings in Danaher were worth $425,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. Legal & General Group Plc grew its stake in Danaher by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after acquiring an additional 139,989 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after acquiring an additional 148,251 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent analyst reports. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. TD Cowen increased their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Thursday, December 5th. Raymond James dropped their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Price Performance

Shares of NYSE DHR opened at $235.91 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1-year low of $217.96 and a 1-year high of $281.70. The company has a market capitalization of $170.39 billion, a price-to-earnings ratio of 45.02, a PEG ratio of 4.23 and a beta of 0.83. The business has a 50-day moving average of $249.91 and a 200-day moving average of $258.14.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 EPS. On average, equities analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.